PREVIEW
OF YOUR NEWS WIDGETHepatitis news and hepatitis widget
Tuesday, October 28, 2008 ( change date )
Early Liver Transplantation Regardless Of Donor Type Increases Long-term Survival
Researchers analyzed 43,497 patients on the UNOS waitlist for a liver transplantation and 22,863 adults who received transplantation to determine the best time strategy for transplantation. They concluded that the increase in posttransplant mortality caused by differences in donor type was vastly offset by the greater benefit in early access to transplantation regardless of donor type.
Medicalnewstoday.com Tuesday, October 28, 2008Cytheris Initiates Asian Phase I/IIa Clinical Trial Of Interleukin-7 (IL-7) As An Immunotherapy In HCV Patients
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a multicenter Phase I/IIa dose escalation study in Taiwan.
Medicalnewstoday.com Tuesday, October 28, 2008Orasure Technologies Files For Fda Approval Of Oraquick(R) Rapid Hepatitis C Test - When Approved, Expected To Be The First Rapid HCV Test In U.S.
OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that it has submitted a pre-market approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for a rapid test for antibodies to the Hepatitis C virus ("HCV") utilizing OraSure Technologies' OraQuick® technology platform. When approved, the OraQuick® HCV test is expected to be the first rapid HCV test approved by the FDA for use in the United States.
Medicalnewstoday.com Tuesday, October 28, 2008
INSTALL YOUR WIDGET